
Julia Spierings

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3614865/publications.pdf Version: 2024-02-01



IIII A SDIEDINCS

#	Article	IF	CITATIONS
1	IL-1α Mediated Chorioamnionitis Induces Depletion of FoxP3+ Cells and Ileal Inflammation in the Ovine Fetal Gut. PLoS ONE, 2011, 6, e18355.	2.5	48
2	Antenatal ureaplasma infection impairs development of the fetal ovine gut in an IL-1-dependent manner. Mucosal Immunology, 2013, 6, 547-556.	6.0	48
3	Heat shock proteins and their immunomodulatory role in inflammatory arthritis. Rheumatology, 2017, 56, 198-208.	1.9	36
4	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Annals of the Rheumatic Diseases, 2020, 79, 1084-1089.	0.9	32
5	Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. Respiratory Medicine, 2021, 187, 106579.	2.9	21
6	Optimal care for systemic sclerosis patients: recommendations from a patient-centered and multidisciplinary mixed-method study and working conference. Clinical Rheumatology, 2019, 38, 1007-1015.	2.2	16
7	Diagnosing and treating antiphospholipid syndrome: a consensus paper. Netherlands Journal of Medicine, 2019, 77, 98-108.	0.5	15
8	Hematopoietic stem-cell transplantation in systemic sclerosis: an update. Current Opinion in Rheumatology, 2018, 30, 541-547.	4.3	14
9	Resetting the T Cell Compartment in Autoimmune Diseases With Autologous Hematopoietic Stem Cell Transplantation: An Update. Frontiers in Immunology, 2018, 9, 767.	4.8	13
10	Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective. Rheumatology, 2020, 59, 2052-2061.	1.9	13
11	Health-related quality of life in patients with immune mediated inflammatory diseases: A cross-sectional, multidisciplinary study. Clinical Immunology, 2020, 214, 108392.	3.2	13
12	Autologous hematopoietic stem cell transplantation in systemic sclerosis: A reset to tolerance?. Immunology Letters, 2018, 195, 88-96.	2.5	12
13	How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?. Rheumatology, 2020, 59, 1226-1232.	1.9	11
14	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open, 2021, 11, e044483.	1.9	11
15	The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation. Clinical and Experimental Immunology, 2020, 201, 34-39.	2.6	9
16	Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110351.	2.7	8
17	Room for improvement in non-pharmacological systemic sclerosis care? — a cross-sectional online survey of 650 patients. BMC Rheumatology, 2020, 4, 43.	1.6	7
18	Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. Rheumatology, 2022, 61, 1476-1486.	1.9	7

JULIA SPIERINGS

1

#	Article	IF	CITATIONS
19	Is There a Place for Hematopoietic Stem Cell Transplantation in Rheumatology?. Rheumatic Disease Clinics of North America, 2019, 45, 399-416.	1.9	6
20	Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis. Rheumatology, 2022, 61, 1948-1956.	1.9	6
21	Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature. Journal of Scleroderma and Related Disorders, 2021, 6, 199-205.	1.7	4
22	PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic. Annals of the Rheumatic Diseases, 2021, 80, 819-820.	0.9	4
23	Nodular Scleroderma. Arthritis and Rheumatology, 2015, 67, 3157-3157.	5.6	3
24	E070 Shared decision-making in progressive diffuse cutaneous systemic sclerosis: a patient's perspective. Rheumatology, 2019, 58, .	1.9	3
25	Living with systemic sclerosis: exploring its impact on caregivers. Disability and Rehabilitation, 2020, 42, 1632-1633.	1.8	3
26	A case of regional migratory osteoporosis. Osteoporosis International, 2018, 29, 507-510.	3.1	2
27	Second autologous haematopoietic stem cell transplantation in systemic sclerosis—a case report. Rheumatology, 2019, 58, 1305-1307.	1.9	2
28	From "being at war―to "getting back on your feet― A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation. Journal of Scleroderma and Related Disorders, 2020, 5, 202-209.	1.7	2
29	Diagnosis and treatment of patients with antiphospholipid syndrome: a mixed-method evaluation of care in The Netherlands. Rheumatology Advances in Practice, 2020, 4, rkaa021.	0.7	2
30	Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case report. Rheumatology, 2021, 60, e326-e328.	1.9	2
31	Physical Therapy in Systemic Sclerosis: The Patient Perspective. Arthritis Care and Research, 2023, 75, 145-151.	3.4	2
32	Physical therapy in patients with systemic sclerosis: physical therapists' perspectives on current delivery and educational needs. Scandinavian Journal of Rheumatology, 2021, , 1-8.	1.1	2
33	Opening the black box of non-pharmacological care in systemic sclerosis: a cross-sectional online survey of Dutch health professionals. Rheumatology International, 2021, 41, 1299-1310.	3.0	2
34	Capillaroscopy of the Nailfold in patients with Peripheral Artery Disease of the Lower Limb (CAPAD) Tj ETQq0 0 0 r	gBT /Over	lock 10 Tf 5
35	Choosing a treatment: how can patients be guided through the labyrinth?. Lancet Rheumatology, The, 2020, 2, e130-e131.	3.9	1

Requirements for systemic sclerosis expert centres in the Netherlands: A Delphi consensus study. 1.7 Journal of Scleroderma and Related Disorders, 2021, 6, 96-101.

JULIA SPIERINGS

#	Article	IF	CITATIONS
37	Combining Data Sets as Well as Therapies Shows Improved Outcome in Connective Tissue Disease–Associated Pulmonary Hypertension. Arthritis and Rheumatology, 2021, 73, 725-727.	5.6	1
38	Information preferences about treatment options in diffuse cutaneous systemic sclerosis: A Delphi consensus study. Journal of Scleroderma and Related Disorders, 2022, 7, 239719832110433.	1.7	1
39	Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features. Journal of Rheumatology, 2022, 49, 544-546.	2.0	1
40	SAT0259â€PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND MAJOR ADVERSE EVENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. , 2019, , .		0
41	AB0650â€PERSPECTIVES AND UNMET NEEDS OF PATIENTS WITH POOR PROGNOSIS SYSTEMIC SCLEROSIS ON AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION CARE: A QUALITATIVE STUDY. , 2019, , .	I	0
42	OP0079â€HPR NON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: OPENING THE BLACK BOX. , 2019, , .		0
43	AB1220â€DISTRIBUTION OF RHEUMATOLOGISTS AND YOUNG RHEUMATOLOGISTS' ORGANIZATIONS ACR THE WORLD: STILL ROOM FOR IMPROVEMENT. , 2019, , .	OSS	0
44	PARE0019â€LIVING WITH SYSTEMIC SCLEROSIS: EXPLORING ITS IMPACT ON CAREGIVERS: A QUALITATIVE STU , 2019, , .	DY.	0
45	Cutibacterium acnes and autoinflammatory bone disease: Case series of three patients. Clinical Immunology, 2020, 219, 108540.	3.2	0
46	P5â€Recognizing the disease, treating the patient: a mixed-method evaluation of care for the antiphospholipid syndrome (APS) in the Netherlands. , 2020, , .		0
47	P151 Self-assessment of scleroderma skin thickness: development and evaluation of the PASTUL questionnaire. Rheumatology, 2021, 60, .	1.9	0
48	POS1419 PREDICTIVE FACTORS FOR PULMONARY PROGRESSION IN PATIENTS WITH CONNECTIVE TISSUE DISEASE AND INTERSTITIAL LUNG DISEASE. Annals of the Rheumatic Diseases, 2021, 80, 993.1-993.	0.9	0
49	AB0914-PAREâ€INFORMATION PREFERENCES ABOUT TREATMENT OPTIONS IN DIFFUSE CUTANEOUS SYSTEMI SCLEROSIS: A DELPHI CONSENSUS STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1478.3-1479.	C _{0.9}	0
50	POS0249â€THE EFFECT OF NASAL STAPHYLOCOCCUS AUREUS COLONIZATION ON DISEASE ACTIVITY AND TH EFFECT OF ANTIBIOTIC TREATMENT IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS; A RETROSPECTIVE COHORT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 346-347.	IE 0.9	0
51	AB0402â€SELF-ASSESSMENT OF SCLERODERMA SKIN THICKNESS: DEVELOPMENT AND VALIDATION OF THE PASTUL QUESTIONNAIRE. Annals of the Rheumatic Diseases, 2021, 80, 1229.2-1230.	0.9	0
52	THU0655â€Patients' evaluation of dutch health care in systemic sclerosis: unmet needs and preferences. , 2018, , .		0
53	Positron Emission Tomography to Improve Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation. Frontiers in Immunology, 0, 13, .	4.8	0